相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma
Jing Li et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2007)
A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109
PJ Van Veldhuizen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
K Gumireddy et al.
CANCER CELL (2005)
Overexpression of polo-like kinase 1 is a common and early event in pancreatic cancer
W Weichert et al.
PANCREATOLOGY (2005)
Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma
W Weichert et al.
BRITISH JOURNAL OF CANCER (2004)
Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma
S Burdette-Radoux et al.
INVESTIGATIONAL NEW DRUGS (2004)
Polo-like kinase I is overexpressed in prostate cancer and linked to higher tumor grades
W Weichert et al.
PROSTATE (2004)
Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles
SH Pun et al.
CANCER BIOLOGY & THERAPY (2004)
Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1
B Spänkuch et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Polo-like kinases and the orchestration of cell division
FA Barr et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Active cyclin B1-Cdk1 first appears on centrosomes in prophase
M Jackman et al.
NATURE CELL BIOLOGY (2003)
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001
SD Baker et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms
AR Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells
B Spänkuch-Schmitt et al.
ONCOGENE (2002)
Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage
N Takai et al.
CANCER LETTERS (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Polo-like kinase-1 is a target of the DNA damage checkpoint
VAJ Smits et al.
NATURE CELL BIOLOGY (2000)
分享论文
